Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 167–173

Current status of interferon alpha in the treatment of chronic hepatitis B


  • J. B. Braken
    • Department of Pharmacology, Division of Pharmacology and PharmacokineticsCatholic University Nijmegen
  • P. P. Koopmans
    • Department of Medicine, Division of General Internal MedicineUniversity Hospital Nijmegen
  • I. P. Van Munster
    • Department of Internal Medicine, Division of Gastroenterology and HepatologyUniversity Hospital Nijmegen
  • F. W. J. Gribnau
    • Department of Pharmacology, Division of Pharmacology and PharmacokineticsCatholic University Nijmegen

DOI: 10.1007/BF01962533

Cite this article as:
Braken, J.B., Koopmans, P.P., Van Munster, I.P. et al. Pharmaceutisch Weekblad Scientific Edition (1992) 14: 167. doi:10.1007/BF01962533


Interferon alpha is the only available therapy for patients with chronic hepatitis B. With interferon alpha 3–15 MU thrice weekly or 5 MU daily during 3–6 months one-third of the patients achieve seroconversion of HBeAg and HBV-DNA together with normalization of aminotransferases and slight improvement of histology. Loss of HBsAg is reported in a minority of responders during treatment, but increases during follow-up. Patients with baseline alanine aminotransferase of at least twice the upper limit of normal and low HBV-DNA concentration achieve the best response rates. HIV-positive patients with low CD4 counts and Asians are poor responders. As side-effects influenza-like symptoms are experienced by almost all patients. Mild leukopenia, thrombocytopenia and decreased hairgrowth are frequently reported. Severe depression, depersonalization and psychosis are reported in a small number of patients but tend to be poorly recognized in some studies. The decision whether dose reduction is indicated seems strongly related to the opinion of the investigator. Although long-term effects on the occurrence of cirrhosis and the development of hepatocellular carcinoma are not available yet, the achieved results are promising.


Clinical trials Hepatitis B Hepatitis B virus Interferon type I Pharmacokinetics Prognosis Side-effects

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992